{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:58:44Z","timestamp":1790373524960,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K02769"],"award-info":[{"award-number":["25K02769"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06800-8","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:25:47Z","timestamp":1790324747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of time to upfront treatment initiation with outcomes in metastatic hormone-sensitive prostate cancer: a 4-month landmark analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Eisuke","family":"Iwaori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hamaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-4079","authenticated-orcid":false,"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"6800_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86:164\u2013182","journal-title":"Eur Urol"},{"key":"6800_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","volume":"23","author":"DE Spratt","year":"2025","unstructured":"Spratt DE, Srinivas S, Adra N et al (2025) Prostate cancer, version 32026, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 23:469\u201393","journal-title":"J Natl Compr Canc Netw."},{"key":"6800_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2026.07.014","author":"G Paras","year":"2026","unstructured":"Paras G, Schweizer MT (2026) Beyond androgen deprivation therapy: next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer. Urol Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.014","journal-title":"Urol Oncol"},{"key":"6800_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70603","volume":"33","author":"H Iwamoto","year":"2026","unstructured":"Iwamoto H, Izumi K, Hori T et al (2026) Survival benefit of ARSI therapy in Japanese mCSPC: a systematic review and meta-analysis. Int J Urol 33:e70603","journal-title":"Int J Urol"},{"key":"6800_CR5","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39:2294\u20132303","journal-title":"J Clin Oncol"},{"key":"6800_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352\u2013360","journal-title":"N Engl J Med"},{"key":"6800_CR7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386:1132\u20131142","journal-title":"N Engl J Med"},{"key":"6800_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737\u2013746","journal-title":"N Engl J Med"},{"key":"6800_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/iju.15647","volume":"32","author":"H Suzuki","year":"2025","unstructured":"Suzuki H, Akamatsu S, Shiota M, Kakiuchi H, Kimura T (2025) Triplet therapy for metastatic castration-sensitive prostate cancer: rationale and clinical evidence. Int J Urol 32:239\u2013250","journal-title":"Int J Urol"},{"key":"6800_CR10","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/iju.70154","volume":"32","author":"Y Yasuda","year":"2025","unstructured":"Yasuda Y, Numao N, Matsumoto S et al (2025) Preliminary report on the efficacy and safety of triplet therapy in patients with metastatic hormone-sensitive prostate cancer: YUSHIMA study. Int J Urol 32:1413\u20131418","journal-title":"Int J Urol"},{"key":"6800_CR11","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.euo.2025.08.007","volume":"8","author":"R Nicoletti","year":"2025","unstructured":"Nicoletti R, Liu AQ, Evans-Axelsson S et al (2025) Treatment Trajectories in Metastatic Hormone-sensitive Prostate Cancer: A PIONEER+ Big Data Analysis. Eur Urol Oncol 8:1340\u20131349","journal-title":"Eur Urol Oncol"},{"key":"6800_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/jjco\/hyag042","volume":"56","author":"K Nishimura","year":"2026","unstructured":"Nishimura K, Hirosuna K, Niigawa H et al (2026) Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis. Jpn J Clin Oncol 56:765\u2013773","journal-title":"Jpn J Clin Oncol"},{"key":"6800_CR13","doi-asserted-by":"publisher","first-page":"e2336604","DOI":"10.1001\/jamanetworkopen.2023.36604","volume":"6","author":"C Corsini","year":"2023","unstructured":"Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M (2023) Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy. JAMA Netw Open 6:e2336604","journal-title":"JAMA Netw Open"},{"key":"6800_CR14","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/iju.70202","volume":"32","author":"Y Yamamoto","year":"2025","unstructured":"Yamamoto Y, Fujimoto S, Hashimoto M et al (2025) Comparison of oncological outcomes of conventional androgen deprivation therapy (ADT) and ADT plus androgen receptor signaling inhibitor in older patients with metastatic castration-sensitive prostate cancer. Int J Urol 32:1650\u20131659","journal-title":"Int J Urol"},{"key":"6800_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jjco\/hyag011","volume":"56","author":"T Uchimoto","year":"2026","unstructured":"Uchimoto T, Hirosuna K, Niigawa H et al (2026) Age-stratified clinical outcomes and adverse events in patients with metastatic castration-sensitive prostate cancer receiving triplet therapy with darolutamide, androgen deprivation therapy, and docetaxel. Jpn J Clin Oncol 56:628\u2013635","journal-title":"Jpn J Clin Oncol"},{"key":"6800_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70226","volume":"13","author":"H Miura","year":"2024","unstructured":"Miura H, Yamamoto H, Okuyama Y et al (2024) Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. Cancer Med 13:e70226","journal-title":"Cancer Med"},{"key":"6800_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/jjco\/hyaf205","volume":"56","author":"Y Tohi","year":"2026","unstructured":"Tohi Y, Kato T, Fujiwara K et al (2026) Real-world efficacy of switching androgen receptor signaling inhibitor therapy following apalutamide discontinuation because of adverse events in advanced prostate cancer: a multicenter study. Jpn J Clin Oncol 56:345\u2013351","journal-title":"Jpn J Clin Oncol"},{"key":"6800_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.urolonc.2025.08.017","volume":"44","author":"BA Maiorano","year":"2026","unstructured":"Maiorano BA, Mercinelli C, Cigliola A et al (2026) Addition of androgen-receptor pathway inhibitors to standard of care in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Urol Oncol 44:27\u201337","journal-title":"Urol Oncol"},{"key":"6800_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2026.111028","volume":"44","author":"E Rinderknecht","year":"2026","unstructured":"Rinderknecht E, Bielstein G, Cathomas R et al (2026) Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: a real-world multicenter retrospective study. Urol Oncol 44:111028","journal-title":"Urol Oncol"},{"key":"6800_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70369","volume":"33","author":"H Takahashi","year":"2026","unstructured":"Takahashi H, Fukuokaya W, Muramoto K et al (2026) Real-world comparative study of apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. Int J Urol 33:e70369","journal-title":"Int J Urol"},{"key":"6800_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70375","volume":"33","author":"K Takahara","year":"2026","unstructured":"Takahara K, Takeuchi A, Saruta M et al (2026) Treatment strategies for metastatic castration-sensitive prostate cancer: current evidence and future directions. Int J Urol 33:e70375","journal-title":"Int J Urol"},{"key":"6800_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2026.05.010","author":"PC Mandel","year":"2026","unstructured":"Mandel PC, Wenzel M, Gandur Quiroga MN et al (2026) Doublet versus triplet therapy in high-volume metastatic hormone-sensitive prostate cancer patients with bone metastases: results from the ARON-3 study. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2026.05.010","journal-title":"Eur Urol Oncol"},{"issue":"211","key":"6800_CR23","volume":"1","author":"R Tanaka","year":"2024","unstructured":"Tanaka R, Hamaya T, Hatakeyama S et al (2024) The impact of delayed administration of androgen-receptor signaling inhibitors (ARSI) on prognosis for mHNPC. J Urol 1(211):e225","journal-title":"J Urol"},{"key":"6800_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/fon-2023-0814","volume":"20","author":"PJ Goebell","year":"2024","unstructured":"Goebell PJ, Raina R, Chen S et al (2024) Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol 20:903\u2013918","journal-title":"Future Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06800-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06800-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06800-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:02:47Z","timestamp":1790370167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06800-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6800"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06800-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shingo Hatakeyama received honoraria from Janssen Pharmaceutical K.K., Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bayer AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd., Bristol-Myers Squibb, Merck Biopharma Co., Ltd. Shingo Hatakeyama also received research funding support from Ferring Pharmaceuticals Co., Ltd., Kaneka Corporation, and Nipro Corporation, and Oyokyo Kidney Research Institute (Public Interest Incorporated Association). Shintaro Narita received honoraria from Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Ltd., Astellas Pharma Inc., AstraZeneca K.K., Kyorin, Sysmex and Bayer AG.\u00a0The other authors have no conflicts of interest to declare. Takahiro Kimura received honoraria from Astellas, AstraZeneca, Bayer, Janssen, Pfizer, Novartis and Takeda. Fumihiko Urabe received honoraria from Janssen Pharmaceutical K.K., Takeda Pharmaceutical Company Ltd., Astellas Pharma Inc., AstraZeneca K.K., and Bayer AG. Tomonori Habuchi received honoraria from Janssen Pharmaceutical K.K., Nippon Kayaku Co., LTD., Takeda Pharmaceutical Company Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Ltd., AstraZeneca K.K., Sanofi S.A., Novartis Pharmaceuticals and Bayer AG.\u00a0Tomonori Habuchi also received research funding supports from Mochida Pharmaceutical Co., Novartis Pharmaceuticals Co, Ltd., and Sysmex Co. The other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective, multi-institutional study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the ethics committee (2019\u2013099-3 and A2018-03) as well as the institutional review boards of all participating hospitals. Informed consent was obtained using an opt-out approach, with study information disclosed on institutional websites to allow patients to decline participation.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors used ChatGPT (OpenAI) for language editing during manuscript preparation. The authors reviewed and revised the output as needed and take full responsibility for the final content.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"698"}}